Meksidol

General characteristics. Structure:

Active agent: ethylmethylhydroxypyridine succinate - 125 mg, excipients: lactoses monohydrate, sodium carboxymethylcellulose (karmelloz of sodium), magnesium stearate, cover: опадрай the II white (macrogoal (polyethyleneglycol), polyvinyl alcohol, talc, titanium dioxide).

Description: Tablets are round, a biconvex form, coated, from color, white to white with a creamy shade.

Pharmacological properties:

Pharmacodynamics. Meksidol is the inhibitor of free radical processes, a membrano-protector possessing anti-hypoxemic, a stress - protective, nootropic, anticonvulsant and anxiolytic action. Drug increases resistance of an organism to influence of various disturbing factors (shock, a hypoxia and ischemia, disturbances of cerebral circulation, intoxication alcohol and antipsychotic means (neuroleptics)). The mechanism of action of Meksidol is caused by his antioxidant, antigipoksantny and membranoprotektorny action. It inhibits peroxide oxidation of lipids, increases activity of a superoxide scavenger, the lipid protein raises a ratio, reduces viscosity of a membrane, increases its flowability. Meksidol modulates activity of membrane-bound enzymes (calcium of independent phosphodiesterase, adenylatecyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GAMK, atsetilkholinovy) that increases their ability of linkng with ligands, promotes preservation of the structurally functional organization of biomembranes, transport of neurotransmitters and improvement of synoptic transfer. Meksidol increases contents in a dopamine brain. Causes strengthening of compensatory activation of aerobic glycolysis and decrease in extent of oppression of oxidizing processes in a tricarbonic acid cycle in the conditions of a hypoxia with increase in content of ATP and creatine phosphate, activation of the power synthesizing functions of mitochondrions, stabilization of cellular membranes. Drug improves metabolism and blood supply of a brain, improves microcirculation and rheological properties of blood, reduces aggregation of thrombocytes. Stabilizes membrane structures of blood cells (erythrocytes and thrombocytes) at hemolysis. Possesses hypolipidemic action, reduces the content of the general cholesterol and lipoproteids of low density. Antistressorny action is shown in normalization of post-stressful behavior, somatovegetativny disturbances, recovery of cycles a dream wakefulness, the broken processes of training and memory, decrease in dystrophic and morphological changes in various structures of a brain. Meksidol possesses the expressed anti-toxic action at an abstinence syndrome. He eliminates neurologic and neurotoxic manifestations of an acute drunkenness, recovers behavior disorders, vegetative functions, and is also capable to remove the cognitive disturbances caused by long reception of ethanol and its cancellation. Under the influence of Meksidol action tranquilizing, antipsychotic, antidepressive, somnolent and anticonvulsants amplifies that allows to lower their doses and to reduce side effects.

Pharmacokinetics. It is quickly soaked up at intake. The maximum concentration at doses of 400 - 500 mg makes 3,5 - 4,0 mkg/ml. It is quickly distributed in bodies and fabrics. The average time of deduction of drug in an organism at intake - 4,9 - 5,2 h. It is metabolized in a liver by a glyukuronkonjyugirovaniye. 5 metabolites are identified: 3 oxypyridines phosphate - are formed in a liver and with the participation of an alkaline phosphatase breaks up to phosphoric acid and 3 oxypyridine; the 2nd metabolite - pharmacological active, is formed in large numbers and it is found in urine on 1 - 2 days after introduction; the 3rd - is brought in large numbers with urine; the 4th and 5th - glyukuronkonjyugata. _Tkh/2 at intake - 2,0 - 2,6 h. It is quickly removed with urine generally in the form of metabolites and in insignificant quantity - in not changed look. It is most intensively removed during the first 4 h after administration of drug. Removal indicators with urine of not changed drug and metabolites have individual variability.

Indications to use:

- Effects of acute disorders of cerebral circulation, including after the tranzitorny ischemic attacks, in subcompensation phase as preventive courses;
- Slight craniocereberal injury, effects of craniocereberal injuries;
- Encephalopathies of various genesis (distsirkulyatorny, ismetabolichesky, posttraumatic, mixed);
- Syndrome of vegetative dystonia;
- Easy cognitive disorders of atherosclerotic genesis;
- Alarming frustration at neurotic and neurosis-like states;
- Stopping of an abstinence syndrome at alcoholism with dominance of neurosis-like and vegetovascular frustration, post-abstinent frustration;
- States after acute intoxication antipsychotic means;
- Asthenic states, and also for prevention of development of somatopathies under the influence of extreme factors and loadings;
- Influence of extreme (stressorny) factors

Route of administration and doses:

Inside, on 125 - 250 mg 3 times a day; the maximum daily dose - 800 mg (6 tablets). Treatment duration - 2 - 6 weeks; for stopping of alcoholic abstinence - 5-7 days. Treatment is stopped gradually, reducing a dose within 2 - 3 days. An initial dose - 125 - 250 mg (1 - 2 tablets) of 1 - 2 time a day with gradual increase to obtaining therapeutic effect. The maximum daily dose - 800 mg (6 tablets).

Features of use:

During treatment it is necessary to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

Emergence of individual side reactions is possible: dispeptic or dispepsichesky character, allergic reactions.

Interaction with other medicines:

Meksidol is combined with all drugs used for treatment of somatopathies. Strengthens effect of benzodiazepine drugs, antidepressants, anxiolytics, anticonvulsants and protivoparkinsonichesky means. Reduces toxic effects of alcohol.

Contraindications:

Acute liver and/or renal failure, the increased individual sensitivity to drug. Due to the insufficient study of effect of drug - children's age, pregnancy, breastfeeding.

Overdose:

At overdose drowsiness development is possible.

Storage conditions:

List B. To store in the dry place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children. A period of validity - 3 years.

Issue conditions:

According to the recipe

Packaging:

Tablets, coated on 125 mg. On 10 tablets in a blister strip packaging from a film of PVC and aluminum foil or on 90 tablets in a plastic can from food plastic. On 1,2,3,5 blister strip packagings on 10 tablets or on 1 plastic can on 90 tablets together with the application instruction in a pack. For the Tablet hospital, coated on 125 mg. On 450 and 900 tablets in a plastic can from food plastic together with application instructions in boxes from a corrugated cardboard.